TLR4 downregulation protects against cisplatin-induced ototoxicity in adult and pediatric patients with cancer
Amit P. Bhavsar(University of Alberta), Andrew Hope(University of Toronto), Erika N. Scott(BC Children's Hospital), Abhinav Thakral(University of California San Francisco Medical Center), Bruce Carleton(University of British Columbia), Colin J.D. Ross(BC Children's Hospital), Lucie Pecheux(University of Alberta), Osvaldo Espin‐Garcia(Western University), Katrina Hueniken(Centre for Addiction and Mental Health), Asna Latif(University of Alberta), Beth Brooks(University of British Columbia), Astrid Billfalk-Kelly(Princess Margaret Cancer Centre), Luna Jia Zhan(University Health Network), Shahrad R. Rassekh(Great Ormond Street Hospital), Mary Mahler(University Health Network), Geoffrey Liu(Princess Margaret Cancer Centre), David Goldstein(Center for Discovery), Maria Spavor(University of Alberta), Yuling Li(Jiangsu Normal University)
Cited by 4
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25
|Nature|2008|1.3k
First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2020|1.1k
Platinum-Induced Ototoxicity in Children: A Consensus Review on Mechanisms, Predisposition, and Protection, Including a New International Society of Pediatric Oncology Boston Ototoxicity Scale
|Journal of Clinical Oncology|2012|375
Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial
|JNCI Journal of the National Cancer Institute|2013|333